COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

OBJECTIVES: The patients with hematological malignancies are a vulnerable group to COVID-19, due to the immunodeficiency resulting from the underlying disease and oncological treatment that significantly impair cellular and humoral immunity. Here we report on a beneficial impact of a passive immunot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transfus Clin Biol
Main Authors: Rnjak, D., Ravlić, S., Šola, A.-M., Halassy, B., Šemnički, J., Šuperba, M., Hećimović, A., Kurolt, I.-C., Kurtović, T., Mačak Šafranko, Ž., Polančec, D., Bendelja, K., Mušlin, T., Jukić, I., Vuk, T., Zenić, L., Artuković, M.
Formato: Artigo
Idioma:Inglês
Publicado em: Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064810/
https://ncbi.nlm.nih.gov/pubmed/33901641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tracli.2021.04.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados